BridgeMD
SIRIUS Sarcoidosis with moderate to severe facial skin involvement: an open multicenter study of the efficacy and safety of oral sirolimus
EU CTIS ID: 2024-514609-76-00
What this study is testing
Evaluating the efficacy of sirolimus on facial skin involvement in sarcoidosis
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- -Age ≥ 18 years < 75 years (men and wome
- -Cutaneous sarcoidosis with facial involvement (diagnosed as follows: compatible clinical appearance showing brownish or yellowish erythematoviolet macules or papules or nodules and compatible histological appearance on either facial or extrafacial skin biopsy confirming the diagnosis of sarcoidosis showing epithelioid and gigantocellular granulomas without caseous necrosis) moderate to severe defined by: SASI (sarcoidosis area and severity index) facial score ≥ 2 AND PGA (Physician's Global Assessment, scale 1 to 10) of skin ≥ 5
- Membership of a French health insurance scheme
- - Patients who have failed at least one line of conventional systemic treatment, or who are naïve to systemic treatment.
- - For women of childbearing age (unless confirmed post-menopausal or sterile), pregnancy test with negative βHCG. Effective contraception by contraceptive pill or intrauterine device must be used during treatment with Sirolimus and for 12 weeks after discontinuation of sirolimus.
- - Patients with written consent
You likely can't join if
- -Severe hepatic impairment (cytolysis (ALT) > 3N and/or cholestasis (PAL) > 3N)
- -Treatment with cyclins for less than 1 month
- -Treatment with topical corticosteroids or tacrolimus for less than 1 week
- -At least one organ affected by sarcoidosis requiring systemic treatment other than sirolimus (oral corticosteroid or systemic per os or parenteral immunosuppressive therapy)
- Cholesterolemia > 3 g/L or triglyceridemia > 4 g/L
- -Concomitant administration of powerful CYP3A4 inhibitors or inducers such as rifampicin, ketoconazole, voriconazole, telithromcyine, diltiazem, verapamil, erythromycin, clarythromycin, ciclosporin.
See the full eligibility criteria
Who can join
- -Age ≥ 18 years < 75 years (men and wome
- -Cutaneous sarcoidosis with facial involvement (diagnosed as follows: compatible clinical appearance showing brownish or yellowish erythematoviolet macules or papules or nodules and compatible histological appearance on either facial or extrafacial skin biopsy confirming the diagnosis of sarcoidosis showing epithelioid and gigantocellular granulomas without caseous necrosis) moderate to severe defined by: SASI (sarcoidosis area and severity index) facial score ≥ 2 AND PGA (Physician's Global Assessment, scale 1 to 10) of skin ≥ 5
- Membership of a French health insurance scheme
- - Patients who have failed at least one line of conventional systemic treatment, or who are naïve to systemic treatment.
- - For women of childbearing age (unless confirmed post-menopausal or sterile), pregnancy test with negative βHCG. Effective contraception by contraceptive pill or intrauterine device must be used during treatment with Sirolimus and for 12 weeks after discontinuation of sirolimus.
- - Patients with written consent
What rules you out
- -Severe hepatic impairment (cytolysis (ALT) > 3N and/or cholestasis (PAL) > 3N)
- -Treatment with cyclins for less than 1 month
- -Treatment with topical corticosteroids or tacrolimus for less than 1 week
- -At least one organ affected by sarcoidosis requiring systemic treatment other than sirolimus (oral corticosteroid or systemic per os or parenteral immunosuppressive therapy)
- Cholesterolemia > 3 g/L or triglyceridemia > 4 g/L
- -Concomitant administration of powerful CYP3A4 inhibitors or inducers such as rifampicin, ketoconazole, voriconazole, telithromcyine, diltiazem, verapamil, erythromycin, clarythromycin, ciclosporin.
- Pregnancy or breast-feeding
- Active infection, including tuberculosis
- Uncontrolled hypertension (SBP > 150 mmHg and/or DBP > 100 mmHg)
- - Patients under guardianship or trusteeship, persons deprived of their liberty, under court protection, under psychiatric care, under restraint, admitted to a health or social establishment for purposes other than those of research
- -cancer patient (except basal cell carcinoma of the skin or cancer in situ of the uterine cervix)
- -Allergy or intolerance to sirolimus or any of its excipients
- -Risk of poor patient compliance.
- -Use of grapefruit or grapefruit juice during treatment
- - patients with fructose or galactose intolerance, glucose-galactose malabsorption, sucrase-isomaltase or Lapp lactase deficiency.
- Peanut or soy allergy
- - Lung or liver transplant patients
- -Treatment with general corticosteroids or immunosuppressive agents (methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine) in the month preceding inclusion.
- Treatment with hydroxychloroquine in the month prior to inclusion
- -Treatment with intralesional corticoids for less than 3 months
- -Treatment with biotherapies (anti-TNFa, anti-IL12/23, anti-IL17A) in the 3 months prior to inclusion
- -Treatment with thalidomide or other imides for less than 3 months
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.